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Abbreviation list 
BMI: body mass index 
CABG: coronary artery bypass graft  
COPD: chronic obstructive pulmonary disease 
CVA: cerebrovascular accident 
DM: diabetes mellitus 
IABP: intraaortic balloon pump 
LAD: left anterior descending  
LMD: left main disease 
LITA: left internal thoracic artery  
LVEF: left ventricular ejection fraction 
OPCAB; off-pump coronary artery bypass  
PSM: propensity score matching 
PVD: peripheral vascular disease 
RCA: right coronary artery  
RITA: right internal thoracic artery (RITA)  
RRT renal replacement therapy 
SMD: standardized mean difference 
sCr: serum creatinine 
SV: saphenous vein  
SWR: sternal wound reconstruction 
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Central message: In a low risk population, Revascularization of the right coronary artery 
system with the right internal thoracic artery was associated with superior late survival when 
compared with saphenous vein grafting 
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Perspective statement: The choice of conduit for the right coronary artery system remains a 
controversial issue. The present long-term propensity score based analysis showed that 
revascularization of the right coronary artery (RCA) system with the right internal thoracic 
artery (RITA) is associated with superior late survival when compared with saphenous vein 
grafting in a low risk population. However, the beneficial impact on survival from the use of 
the RITA was delayed by as much as 9 to 10 years. This supports the view that, the use of 
RITA to graft the RCA should be encouraged especially in patients with long life expectancy.  
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Abstract 
Objectives: While the use of the right internal thoracic artery (RITA) as second arterial conduit 
to graft the left coronary system has been consistently shown to provide a survival benefit when 
compared to saphenous vein graft (SVG), the choice of conduit for the right coronary artery 
(RCA) system remains controversial. We compared long term (>15 years) survival in patients 
who underwent RITA-RCA versus SV-RCA grafting at a single institution. 
Methods: The study population consisted of 7223 patients undergoing coronary artery bypass 
graft surgery. Of them 245 (3.4%) and 6978 (96.6%) received RITA-RCA and SV-RCA graft 
respectively. Propensity score (PS) matching and time-segmented Cox regression were used to 
compare the two groups.  
Results: Survival probability at 5,10 and 15 years were 95.9%[93.4-98.4] versus 96.0%[94.3-
97.8], 89.8%[85.9-93.7] versus 88.0%[85.0-91.0] and 82.9%[77.6-88.2] versus 76.3[72.0-
80.5] in the RITA-RCA and SVG-RCA group respectively (Figure 2). Time segmented Cox 
regression showed that during the first 9 years, the two strategy were associated with 
comparable risk of death (HR 1.13;95%CI 0.67-1.90; P=0.65) but beyond 9 years, the RITA-
RCA was associated with a significantly lower risk of death (HR 0.43;95%CI 0.22-0.84; 
P=0.01).  
Conclusions: Revascularization of the RCA system with the RITA was associated with 
superior late survival when compared with SVG. This supports the view that, the use of RITA 
to graft the RCA should be encouraged especially in patients with long life expectancy.  
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The choice of conduit for coronary artery bypass graft (CABG) is widely debated by cardiac 
surgeons [1]. While the use of the right internal thoracic artery (RITA) in addition to the left 
internal thoracic artery (LITA) to graft the left coronary system has been consistently shown 
to provide a survival benefit when compared to saphenous vein graft (SVG) [2], the choice of 
conduit for the right coronary artery (RCA) system remains a controversial issue. To date, the 
only randomized controlled trial (RCT) designed to compare long term survival after CABG 
with bilateral versus single internal thoracic artery grafting (ART trial) included only patients 
receiving the arterial conduit on the left coronary system [3]. Observational studies comparing 
RITA-RCA versus SVG-RCA have shown conflicting results. Some reports have suggested 
that the RITA grafting improves long-term survival over LITA plus SVGs, and propose that 
the RITA should be used to bypass the circumflex artery rather than the RCA [4]. Others 
documented equivalent long-term results with the use of the RITA, whether applied to the left 
or RCA system [5,6]. Current comparison between RITA vs SVG for grafting the RCA are 
limited by relatively short follow-up (~5 years). In the present study, we aimed to get further 
insights into the role of RITA graft for revascularization of the RCA by comparing long term 
(>15 years) survival in patients who underwent RITA-RCA versus SVG-RCA strategy at a 
single institution. We also aimed to investigate whether different RITA-RCA configurations 
(free versus in-situ grafts) were associated with similar survival rates.  
Methods and Methods 
The study was conducted in accordance with the principles of the Declaration of Helsinki. The 
local audit committee approved the study, and the requirement for individual patient consent 
was waived. We retrospectively analysed prospectively collected data from The National 
Institute for Cardiovascular Outcomes Research National Adult Cardiac Surgery Audit registry 
on 1 June 2015 for all isolated first time CABG procedures performed at the Bristol Heart 
Institute (Bristol, United Kingdom) from 1996 to April 2015. Reproducible cleaning 
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algorithms were applied to the database and regularly updated as required. Briefly, duplicate 
records and non-adult cardiac surgery entries were removed; transcriptional discrepancies were 
harmonized; and clinical conflicts and extreme values were corrected or removed. The data 
were returned regularly to the local units for validation. Further details and definition of 
variables are available at http://www.ucl.ac.uk/nicor/audits/adultcardiac/datasets. Among 
15119 isolated first time CABG cases performed during the study period, we selected subjects 
who met the following criteria: multivessel coronary artery disease including left main and/or 
left anterior descending (LAD) coronary disease; requiring at least 2 grafts; CABG  performed 
by using the following strategies: left internal thoracic artery (LITA) used to graft the LAD 
territory and RITA graft the RCA with or without additional SVG (RITA-RCA group) or LITA 
to LAD graft with SVG to RCA with or without additional SVG for non-RCA target (SVG-
RCA group). Exclusion criteria were: 1) RITA graft to target other than RCA; 2) radial artery 
used; 3) LITA to target other than LAD; 4) RCA not grafted; right gastroepiploic artery used. 
In the present series, the RITA and SV graft were used to graft the RCA in case of target 
stenosis ≥75% [8]. SVGs were used proximally connected to the ascending aorta in all cases. 
The internal thoracic artery was harvested as a pedicle in all cases. LITA was used as in situ 
graft that remained proximally connected to its respective subclavian artery and distally 
connected to the LAD. The RITA was used as both in situ graft or as a free graft proximally 
connected to ascending aorta. 
Study Endpoints 
All-cause mortality during follow-up was the primary endpoint. This is considered the most 
robust and unbiased index in cardiovascular research because no adjudication is required, thus 
avoiding inaccurate or biased documentation and clinical assessments [9]. Information about 
post-discharge mortality tracking was available for all patients (100%) and was obtained by 
linking the institutional database with the National General Register Office. Other short-term 
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outcomes analysed were: re-exploration for bleeding, need for sternal wound reconstruction, 
postoperative cerebrovascular accident (CVA) (defined as any confirmed neurologic deficit of 
abrupt onset that did not resolve within 24 hours), postoperative renal replacement therapy 
(RRT), need for postoperative intra-aortic balloon pump (IABP) and in hospital mortality.  
Pre-treatment variables 
The effect of RITA-RCA vs SV-RCA on outcomes of interest was adjusted for the following 
pre-treatment variables: age, gender, body mass index (BMI); Canadian Cardiovascular 
Society functional class III-IV; New York Heart Association grade III or IV; previous 
myocardial infarction (MI) within 30 days; previous percutaneous coronary intervention (PCI); 
diabetes mellitus (DM) on oral treatment or on insulin; chronic obstructive pulmonary disease 
(COPD); current smoking; serum creatinine ≥200 mmol/l, previous CVA; peripheral vascular 
disease (PVD); preoperative atrial fibrillation (AF); left ventricular ejection fraction (LVEF) 
between 30% and 49%; LVEF less than 30%; non elective admission, cardiogenic shock; 
preoperative IABP; left main disease (LMD); concomitant circumflex artery disease grafted; 
total number of grafts; off-pump coronary artery bypass and eras of surgery.  
Statistical Analysis 
For baseline characteristics, variables are summarized as means ± standard deviation for 
continuous variables and frequencies and proportions for categorical variables. Multiple 
imputation was used to address missing data (http://www.jstatsoft.org/v45/i07/). To control for 
measured potential confounders in the data set, a propensity score (PS) was generated for each 
patient from a multivariable logistic regression model that was based on pre-treatment 
covariates as independent variables with treatment type (RITA-RCA vs SVG-RCA) as a binary 
dependent variable (http://CRAN.Rproject.org/package=nonrandom) [10]. The resulting PS 
represented the probability of a patient having RITA to RCA graft. PS model discrimination 
power and fit were tested using c-statistic and the Hosmer-Lemeshow goodness-of-fit 
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(https://CRAN.R-project.org/package=ResourceSelection). Pairs of patients undergoing 
RITA-RCA and SVG-RCA grafting were derived with greedy 1:2 matching with a caliper of 
width of 0.2 SD of the logit of the PS. A matching ratio ≥3 resulted in significantly imbalance 
between the two groups. The quality of the match was assessed by comparing selected pre-
treatment variables in PS-matched patients by using the standardized mean difference, by 
which an absolute standardized difference of greater than 10% is suggested to represent 
meaningful covariate imbalance [11]. Analytic methods for the estimation of the treatment 
effect in the matched sample were used. McNemar test was used to compare short term 
outcomes in the matched sample [10]. Kaplan–Meier analyses was used to calculate survival 
rates. Conditional Cox regression model stratified for matched pairs was used to estimate the 
treatment effect on survival [10]. Residual weights were used to test the proportional hazard 
assumption and in case of violation, time segmented Cox regression before and after the curves 
diverged was used (http://CRAN.R-project.org/package=survival) [12]. All statistical analysis 
were performed using R Statistical Software (version 3.2.3; R Foundation for Statistical 
Computing, Vienna, Austria). 
 Results 
The final study population consisted of 7223 patients. Of them 245 (3.4%) and 6978 (96.6%) 
received RITA-RCA and SVG-RCA graft respectively (Supplementary Figure 1 and Figure 1). 
RITA was used as in situ in 198 (81%) and as free graft in 47 (19%). Baseline characteristics 
of the two groups before and after PS matching are reported in Table 1. Patients receiving 
RITA-RCA were significantly younger, less likely to be female and presented a lower burden 
of comorbidities. Patients receiving SVG-RCA were more likely to have LMD and circumflex 
artery disease and undergo off-pump surgery. Finally RITA-RCA was more likely performed 
during the first study period. PS matching selected 490 patients receiving SVG-RCA graft who 
comparable to those receiving RITA-RCA graft. (SMD<10%). The PS model presented a very 
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good discriminatory power (C-statistics 0.93) to predict the treatment status with no evidence 
of poor fit (Hosmer and Lemeshow goodness of fit test P=0.25; Supplementary Figure 2).  
Short term outcomes 
Short term outcomes are reported in Table 2. The two groups presented comparable incidence 
of postoperative complications rates. In-hospital mortality rate was comparable between RITA-
RCA (0.4%) and SV-RCA graft (0.6%).    
Survival 
After a mean follow-up time of 8±5 years (max 17 years) there were 36 and 1948 deaths in the 
RITA-RCA and RITA-SV group respectively. After PS matching, survival probability at 5,10 
and 15 years were 95.9%[93.4-98.4] versus 96.0%[94.3-97.8], 89.8%[85.9-93.7] versus 
88.0%[85.0-91.0] and 82.9%[77.6-88.2] versus 76.3[72.0-80.5] in the RITA-RCA and SVG-
RCA group respectively (Figure 2). Kaplan Meier analysis showed that the two survival curves 
were superimposed up to ~9 years. At ∼9 years, the survival curves crossed and, between 10 
and 15 years, the RITA-RCA group demonstrated superior survival (residual weights test 
P=0.03). Time segmented Cox regression showed that during the first 9 years, the two strategy 
were associated with comparable risk of death (HR 1.13;95%CI 0.67-1.90; P=0.65) but beyond 
9 years, the RITA-RCA was associated with a significantly lower risk of death (HR 
0.43;95%CI 0.22-0.84; P=0.01). When the RITA-RCA group was divided in free RITA-RCA 
graft (n=47) and in situ RITA-RCA graft (n=198) survival probability at 5, 10 and 15 years 
were 91.1 %[82.9-99.4] versus 97.0[94.6-99.4], 81.7[70.3-93.2] versus 91.6%[87.7-95.6] and 
71.1[57.1-85.1] versus 85.5%[80.0-91.1] respectively. Patients receiving free RITA-RCA and 
in-situ RITA-RCA were separately compared to 1:2 matched pairs of patients receiving SV-
RCA (Supplementary Table 1 and Supplementary Table 2). In situ RITA-RCA (HR 0.60; 
95%CI 0.35-0.98; P=0.04; Weight residual test P=0.12; Figure 3 right) but not free RITA-RCA 
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(HR 1.03; 95%CI 0.47-2.26; P=0.94; residual weights test P=0.58; Figure 3 left) was associated 
with better survival when compared to SVG-RCA.   
Discussion 
The main findings of the present analysis is that when the use of the RITA to graft the right 
coronary artery system was associated with superior long term survival compared to the SVG. 
Survival benefit was no apparent during the first 9 years but became evident afterwards. Our 
subgroup analysis suggested that this benefit might be more relevant with in-situ instead of free 
RITA graft configuration. However, free RITA graft subgroup was particularly small to draw 
any definitive conclusion. RITA graft was not associated with increased postoperative 
complications or hospital mortality.  
In the present cohort, the use of RITA for the RCA system was relatively low and it was mainly 
used during the first part of the study period and never gained popularity in our centre. This 
observation might be partially explained by a larger body of evidence supporting a survival 
benefit from RITA when used to graft the left coronary artery system. In fact in the present 
cohort, in the majority of cases, the RITA was used to graft the left anterior descending artery 
(n=273) and the circumflex artery (n=414). Another possible explanation for preferring the 
RITA for the left coronary system is the increased technical complexity in particular when the 
RITA is used as in-situ graft to the posterior descending artery which can potentially result in 
graft kinking and stretching.   
While the use of the RITA to graft the left coronary system has been consistently reported to 
be associated to excellent patency rate [13] and improved outcomes [14], the role of the RITA 
for revascularization of the RCA remains controversial [15]. Angiographic follow-up studies 
have demonstrated a hierarchy of RITA patency; best for the LAD, then the circumflex, and 
lowest to the RCA [8]. Although, a similar hierarchy of patency has been also observed for 
SVG, it has been shown that the patency of the RITA is significantly affected by the stenosis 
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of the recipient RCA [13], most likely as a result of competitive flow or poorer runoff [16]. 
However, when the RITA is used to bypass high grade proximal stenosis [17] it has been shown 
to achieve excellent patency rate [16,17]. The variability of RITA-RCA graft patency rate 
according to the severity of the RCA stenosis might partially account for conflicting findings 
reported on survival benefit from the use of RITA instead of SVG.  Schmidt et al. [4] observed 
long-term survival of 93% when the RITA was used to bypass left-sided coronary arteries but 
only 70% when grafted to the RCA system after a mean follow-up of 9.2 years (P=0.02). In 
contrast, Kurlansky et al. [5] found similar survival after a mean follow-up of 12 years. In their 
series, in situ grafting was used in the majority of cases (approximately 98% of arteries grafted) 
and when the RITA was used to graft the RCA, efforts were made to graft severely stenosed 
vessels and distal branches rather than the main RCA. In this context, also, Sabik at al. [6] were 
able to document equivalent long-term results with the use of the RITA, whether applied to the 
left or RCA system, and this was attributed to careful patient selection. Two important factors 
were: (1) RCA stenosis of 70% to 90% with viable myocardium in its distribution; and (2) 
freedom from distal stenosis. In the present cohort, the RITA was used only in case of native 
vessel stenosis >75% and this can partially explain the observed survival benefit from the use 
of RITA over SVG.  
In the present long term survival analysis, we found that when compared to SV, the use of 
RITA for revascularization of the RCA system was associated with improved late survival. 
The beneficial impact on survival from the use of the RITA was delayed by as much as 9 to 
10 years but persisted beyond that period. The present findings seem to be supported by 
recently published interim analysis of the ART trial which did not show any mid-term benefit 
from the RITA grafted to the left coronary system [3]. A possible explanation for these 
findings is that SVG failure rate increases significantly after 5 years and a longer follow-up is 
needed to demonstrate a survival benefit from the use of RITA regardless the coronary artery 
 13 
 
system treated. The present study population included relatively young subjects with low 
burden of comorbidities and anticipated prolonged life expectancy and therefore the use of 
the RITA may be less appreciated in older patients with coexistent morbidities and limited 
life expectancy.  
We attempted to compare in situ vs free RITA graft configuration for the RCA and we found 
some evidence towards better results with in-situ configuration. However, very few subjects 
received free RITA graft and the present subgroup analysis was largely underpowered to detect 
significant difference in late survival in this group. Despite concerns that direct ascending aorta 
RITA inflow may lead to vascular wall “reactivity” have been raised, this aspect remains 
controversial with conflicting findings reported . Calafiore and colleagues [18] initially 
reported that the patency rate of the free right ITA proximally anastomosed to the aorta was 
inferior to that anastomosed to the left ITA. They suggested that the reason for this poor graft 
patency rate was because of a mismatch between the aorta and the conduit wall and a difference 
in the flow pattern [18]. A previous report from Buxton and colleagues, who concluded that 
proximal attachment to the aorta compared with in situ RITA grafts resulted in a 2-fold increase 
in the risk of graft failure [8]. On the other hand, large angiographic studies have confirmed 
excellent patency rates with free RITA graft [13,19]. Tatoulis et al [13], found that in-situ RITA 
(n=450), and free RITA grafts (n=541) had similar ten-year patencies (89% vs 91%; P=0.44). 
Interestingly, they found that for the posterior descending artery, in situ and free RITA grafts 
provided similar patency rates (P=0.67) but for the main RCA, in situ RITA patency was 
associated with lower patency rate  compared to free RITA (73.8% versus 93.1%; P=0.02). 
Finally, we found that the RITA-RCA graft can be performed without increasing the risk of 
postoperative complications including sternal wound reconstruction. Bilateral internal thoracic 
arteries harvesting has been consistently demonstrated to be associated with increased sternal 
wound complications especially when these conduits are harvested as pedicle [20]. For the he 
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present analysis, only information regarding sternal wound reconstruction were available and 
we cannot exclude that the use of the RITA was associated with increased incidence of sternal 
wound infection not requiring sternal rewiring.  
The present analysis has intrinsic limitations. The RITA-RCA bypass was used very 
infrequently in general, and was primarily used in the first part of the series. Differences 
between the two groups can be caused by variation of patients risk profile across different 
surgical eras. PS matching can adjust only for measurable and included variables and we cannot 
exclude a selection bias based on non-measurable “eye-ball” variables (with the RITA reserved 
to healthier and better patients). No follow-up data were available to compare the groups with 
respect to the cause of death (cardiac vs non-cardiac), need for repeated revascularization, and 
graft patency. Therefore, we can only speculate that the mechanism beyond the superior long-
term survival observed in our RITA group is related to the better patency rate of the RITA over 
the SVG. Finally the analysis for the free RITA-RCA cohort was underpowered to detect 
significant difference between groups.  
In conclusion, in a selected low risk group of patients, revascularization of the RCA system 
with the RITA was associated with superior late survival (beyond 9 year) when compared with 
SVG. Further evidence are needed to clarify the best configuration for RITA-RCA graft. This 
supports the view that, the use of RITA to graft the RCA should be encouraged especially in 
patients with long life expectancy.  
 15 
 
Figures Legends 
Central Picture: Survival in the propensity score matched sample according to use of the right 
internal thoracic artery (RITA) used as in situ or free graft or saphenous vein (SV) for 
revascularization of the right coronary artery. 
Figure 1: Use of the right internal thoracic artery (RITA) or saphenous vein graft (SVG) for 
revascularization of the right coronary artery during the study period.  
Figure 2. Survival in the propensity score matched sample according to use of the right internal 
thoracic artery (RITA) or saphenous vein graft (SVG) for revascularization of the right 
coronary artery (RCA).  
Figure 3. Survival after propensity score matching according to use of the right internal thoracic 
artery (RITA) used as free (left) or in situ (right) graft versus saphenous vein graft (SVG) for 
revascularization of the right coronary artery (RCA).  
Supplementary Figure 1. Flow chart for patient selection (CABG: Coronary artery bypass 
grafting; RITA: right internal thoracic artery; RA: radial artery; LITA: left internal thoracic 
artery; RCA: right coronary artery; RGEA: right gastroepiploic artery) 
Supplementary Figure 2: Area under the ROC curve (C statistics) for the propensity score 
model and relative Hosmer and Lemeshow goodness of fit test  
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Table 1. Patients’ characteristics distribution before and after matching in the RITA-RCA and SVG-RCA groups 1 
 RITA-RCA SVG-RCA 
(unmatched) 
 P SMD 2:1 Matched 
SVG-RCA 
P SMD 
n  245 6978   490   
Age (mean (sd))  56 (8) 68 (8) <0.001 1.547 57 (8) 0.09 0.09 
Female n(%) 24 ( 9.8) 1307 (18.7) 0.001 0.258 47 ( 9.6) 1.000 0.007 
BMI (mean (sd))  27.59 (3.26) 27.79 (4.40) 0.485 0.051 27.64 (4.06) 0.873 0.013 
CCS III-IV n(%) 122 (49.8) 3409 (48.9) 0.822 0.019 237 (48.4) 0.774 0.029 
NYHA III-IV n(%) 55 (22.4) 2156 (30.9) 0.006 0.192 116 (23.7) 0.781 0.029 
MI within 30 days n(%) 13 ( 5.3) 1488 (21.3) <0.001 0.485 28 ( 5.7) 0.955 0.018 
PCI n(%) 3 ( 1.2) 336 ( 4.8) 0.014 0.211 6 ( 1.2) 1.000 <0.001 
DM orally treated  n(%) 4 ( 1.6) 808 (11.6) <0.001 0.409 5 ( 1.0) 0.722 0.054 
DM on insulin n(%) 7 ( 2.9) 572 ( 8.2) 0.004 0.235 8 ( 1.6) 0.406 0.083 
Smoking n(%) 50 (20.4) 849 (12.2) <0.001 0.225 96 (19.6) 0.870 0.020 
Creatinine>200mmol/l n(%) 3 ( 1.2) 216 ( 3.1) 0.136 0.129 7 ( 1.4) 1.000 0.018 
COPD n(%) 5 ( 2.0) 571 ( 8.2) 0.001 0.282 12 ( 2.4) 0.931 0.028 
CVA n(%) 3 ( 1.2) 290 ( 4.2) 0.034 0.182 6 ( 1.2) 1.000 <0.001 
PVD n(%) 21 ( 8.6) 780 (11.2) 0.241 0.087 35 ( 7.1) 0.589 0.053 
AF n(%) 5 ( 2.0) 249 ( 3.6) 0.272 0.093 10 ( 2.0) 1.000 <0.001 
LVEF 30-49% n(%) 31 (12.7) 1705 (24.4) <0.001 0.307 68 (13.9) 0.731 0.036 
LVEF<30% n(%) 2 ( 0.8) 387 ( 5.5) 0.002 0.272 5 ( 1.0) 1.000 0.021 
Shock n(%) 0 ( 0.0) 36 ( 0.5) 0.506 0.102 0 ( 0.0) - - 
Preop IABP n(%) 1 ( 0.4) 120 ( 1.7) 0.187 0.128 1 ( 0.2) 1.000 0.037 
Non-elective n(%) 99 (40.4) 3433 (49.2) 0.008 0.177 199 (40.6) 1.000 0.004 
LMD n(%) 18 ( 7.3) 1707 (24.5) <0.001 0.481 33 ( 6.7) 0.878 0.024 
Circumflex artery grafted n(%) 104 (42.4) 5469 (78.4) <0.001 0.790 223 (45.5) 0.479 0.062 
Tot n grafts (mean (sd))  2.73 (0.80) 3.07 (0.62) <0.001 0.469 2.79 (0.72) 0.346 0.072 
Off-pump n(%) 60 (24.5) 3051 (43.7) <0.001 0.414 128 (26.1) 0.698 0.038 
Era of surgery (mean (sd))  2000 (4) 2005 (6) <0.001 1.140 2000 (4) 0.367 0.072 
RITA: right internal thoracic artery; SVG: saphenous vein graft; SMD: standardized mean difference; BMI: body mass index; CCS: Canadian 2 
Cardiovascular Society; NYHA: New York American Heart; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; CVA: 3 
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cerebrovascular accident; PVD: peripheral vascular disease; AF: Atrial Fibrillation; LVEF: left ventricular ejection fraction; IABP: intraaortic 4 
balloon pump; LMD: left main disease 5 
  6 
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Table 2. Operative outcomes  7 
RITA: right internal thoracic artery; SVG: saphenous vein graft   8 
 RITA-RCA SVG-RCA  
(unmatched) 
P 2:1 Matched 
SVG-RCA 
P 
n   245 6978  490  
Mortality within 30 days n(%)  1 (0.4) 103 (1.5) 0.269 3 (0.6) 1.000 
Re-exploration for bleeding n(%) 9 (3.7) 215 (3.1) 0.735 12 (2.4) 0.481 
Sternal wound reconstruction n(%)  0 (0.0) 48 (0.7) 0.367 0 (0.0) - 
Postoperative stroke n(%) 0 (0.0) 114 (1.6) 0.079 6 (1.2) 0.192 
Postoperative Dialysis n(%)  3 (1.2) 173 (2.5) 0.298 5 (1.0) 1.000 
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Supplementary Table 1. Patients’ characteristics distribution before and after matching in the in-situ RITA-RCA and SVG-RCA groups 9 
RITA: right internal thoracic artery; SVG: saphenous vein graft; SMD: standardized mean difference; BMI: body mass index; CCS: Canadian 10 
Cardiovascular Society; NYHA: New York American Heart; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; CVA: 11 
 In-situ RITA-
RCA 
SVG-RCA 
(unmatched) 
P SMD 2:1 Matched 
SVG-RCA 
P SMD 
n  198 6978   396   
Age (mean (sd))  56 (7) 68 (8) <0.001 1.597 56 (8) 0.759 0.027 
Female n(%) 20 (10.1) 1307 (18.7) 0.003 0.248 41 (10.4) 1.000 0.008 
BMI (mean (sd))  27.71 (3.05) 27.79 (4.40) 0.816 0.019 27.92 (4.41) 0.545 0.056 
CCS III-IV n(%) 97 (49.0) 3409 (48.9) 1.000 0.003 194 (49.0) 1.000 <0.001 
NYHA III-IV n(%) 43 (21.7) 2156 (30.9) 0.007 0.210 93 (23.5) 0.704 0.042 
MI within 30 days n(%) 9 ( 4.5) 1488 (21.3) <0.001 0.516 21 ( 5.3) 0.842 0.035 
PCI n(%) 3 ( 1.5) 336 ( 4.8) 0.047 0.189 8 ( 2.0) 0.914 0.038 
DM orally treated  n(%) 4 ( 2.0) 808 (11.6) <0.001 0.387 9 ( 2.3) 1.000 0.017 
DM on insulin n(%) 4 ( 2.0) 572 ( 8.2) 0.003 0.283 12 ( 3.0) 0.654 0.064 
Smoking n(%) 43 (21.7) 849 (12.2) <0.001 0.257 94 (23.7) 0.654 0.048 
Creatinine>200mmol/l n(%) 1 ( 0.5) 216 ( 3.1) 0.059 0.196 2 ( 0.5) 1.000 <0.001 
COPD n(%) 4 ( 2.0) 571 ( 8.2) 0.003 0.283 8 ( 2.0) 1.000 <0.001 
CVA n(%) 1 ( 0.5) 290 ( 4.2) 0.017 0.244 3 ( 0.8) 1.000 0.032 
PVD n(%) 14 ( 7.1) 780 (11.2) 0.089 0.143 23 ( 5.8) 0.674 0.051 
AF n(%) 3 ( 1.5) 249 ( 3.6) 0.176 0.131 7 ( 1.8) 1.000 0.020 
LVEF 30-49% n(%) 22 (11.1) 1705 (24.4) <0.001 0.354 50 (12.6) 0.689 0.047 
LVEF<30% n(%) 2 ( 1.0) 387 ( 5.5) 0.009 0.257 4 ( 1.0) 1.000 <0.001 
Shock n(%) 0 ( 0.0) 36 ( 0.5) 0.615 0.102 0 ( 0.0) - - 
Preop IABP n(%) 1 ( 0.5) 120 ( 1.7) 0.303 0.116 3 ( 0.8) 1.000 0.032 
Non-elective n(%) 81 (40.9) 3433 (49.2) 0.026 0.167 167 (42.2) 0.837 0.026 
LMD n(%) 16 ( 8.1) 1707 (24.5) <0.001 0.455 30 ( 7.6) 0.957 0.019 
Circumflex artery grafted n(%) 86 (43.4) 5469 (78.4) <0.001 0.767 186 (47.0) 0.467 0.071 
Tot n grafts (mean (sd))  2.73 (0.78) 3.07 (0.62) <0.001 0.487 2.80 (0.70) 0.247 0.099 
Off-pump n(%) 42 (21.2) 3051 (43.7) <0.001 0.495 89 (22.5) 0.807 0.031 
Era of surgery (mean (sd))  2000 (4) 2005 (5) <0.001 1.163 2000 (5) 0.133 0.09 
 20 
 
cerebrovascular accident; PVD: peripheral vascular disease; AF: Atrial Fibrillation; LVEF: left ventricular ejection fraction; IABP: intraaortic 12 
balloon pump; LMD: left main disease  13 
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Supplementary Table 2. Patients’ characteristics distribution before and after matching in the free RITA-RCA and SVG-RCA groups 14 
 Free RITA-
RCA 
SVG-RCA 
(unmatched) 
P SMD 2:1 Matched 
SVG-RCA 
P SMD 
n        47      6978               94         
Age (mean (sd))     56 (9)     68 (8)   <0.001    1.360      57 (8)    0.531    0.09 
Female n(%)        4 ( 8.5)       1307 (18.7)     0.109    0.301          5 ( 5.3)     0.715    0.126   
BMI (mean (sd))     27.06 (4.04)     27.79 (4.40)    0.260    0.172      27.75 (3.83)    0.322    0.176   
CCS III-IV n(%)       25 (53.2)       3409 (48.9)     0.655    0.087         58 (61.7)     0.432    0.173   
NYHA III-IV n(%)       12 (25.5)       2156 (30.9)     0.525    0.119         23 (24.5)     1.000    0.025   
MI within 30 days n(%)        4 ( 8.5)       1488 (21.3)     0.050    0.366          8 ( 8.5)     1.000   <0.001   
PCI n(%)        0 ( 0.0)        336 ( 4.8)     0.231    0.318          0 ( 0.0)   - - 
DM orally treated  n(%)        0 ( 0.0)        808 (11.6)     0.024    0.512          0 ( 0.0)   - - 
DM on insulin n(%)        3 ( 6.4)        572 ( 8.2)     0.853    0.070          5 ( 5.3)     1.000    0.045   
Smoking n(%)        7 (14.9)        849 (12.2)     0.729    0.080         15 (16.0)     1.000    0.029   
Creatinine>200mmol/l n(%)        2 ( 4.3)        216 ( 3.1)     0.972    0.062          7 ( 7.4)     0.715    0.136   
COPD n(%)        1 ( 2.1)        571 ( 8.2)     0.213    0.276          2 ( 2.1)     1.000   <0.001   
CVA n(%)        2 ( 4.3)        290 ( 4.2)     1.000    0.005          3 ( 3.2)     1.000    0.056   
PVD n(%)        7 (14.9)        780 (11.2)     0.567    0.111         16 (17.0)     0.936    0.058   
AF n(%)        2 ( 4.3)        249 ( 3.6)     1.000    0.035          6 ( 6.4)     0.898    0.095   
LVEF 30-49% n(%)        9 (19.1)       1705 (24.4)     0.503    0.128         16 (17.0)     0.938    0.055   
LVEF<30% n(%)        0 ( 0.0)        387 ( 5.5)     0.180    0.343          0 ( 0.0)   - - 
Shock n(%)        0 ( 0.0)         36 ( 0.5)     1.000    0.102          0 ( 0.0)   - - 
Preop IABP n(%)        0 ( 0.0)        120 ( 1.7)     0.732    0.187          0 ( 0.0)   - - 
Non-elective n(%)       18 (38.3)       3433 (49.2)     0.179    0.221         35 (37.2)     1.000    0.022   
LMD n(%)        2 ( 4.3)       1707 (24.5)     0.002    0.602          6 ( 6.4)     0.898    0.095   
Circumflex artery grafted n(%)       18 (38.3)       5469 (78.4)    <0.001    0.890         32 (34.0)     0.756    0.089   
Tot n grafts (mean (sd))      2.77 (0.89)      3.07 (0.62)    0.001    0.397       2.85 (0.79)    0.564    0.09 
Off-pump n(%)       18 (38.3)       3051 (43.7)     0.549    0.110         36 (38.3)     1.000   <0.001   
Era of surgery (mean (sd))   2000 (4)   2005 (5)   <0.001    1.041   2000 (4)    0.942    0.013   
RITA: right internal thoracic artery; SVG: saphenous vein graft; SMD: standardized mean difference; BMI: body mass index; CCS: Canadian 15 
Cardiovascular Society; NYHA: New York American Heart; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; CVA: 16 
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cerebrovascular accident; PVD: peripheral vascular disease; AF: Atrial Fibrillation; LVEF: left ventricular ejection fraction; IABP: intraaortic 17 
balloon pump; LMD: left main disease18 
 23 
 
Appendix A: R codes for  19 
### packages used for analysis ### 20 
require (survival) 21 
require (nonrandom) 22 
require (prodlim)  23 
###PS model### 24 
ps=pscore(RITA~Age+Female+BMI+CCS+NYHA+MI30d+PCI+DMO+DMI+smoking+ren25 
al+COPD+CVA+PVD+AF+LV5030+Lvless30+shock+preopIABP+non_elective+LMD+CX26 
+NGrafts+OPCAB+YOP, rdata) 27 
###PS matching 1:2#### 28 
psm=ps.match(ps, ratio=2) 29 
###new dataset with matched pairs only and  30 
m.data=psm$data.matched 31 
### Proportional Hazard check#### 32 
Cox.zph(coxph(Surv(time, death==1)~RITA+strata(match.index), m.data)) 33 
### Survival curves plot ###  34 
plot(prodlim(Hist(time/365.25, death==1)~RITA, m.data), legend.legend=c('SVG-35 
RCA','RITA-RCA'), at.risk.at=c(0,5,10,15)) 36 
##time segmented analysis @ 9 years ### 37 
#1# time and event variables censored @ 9 years ### 38 
m.data$M9y=m.data$death 39 
m.data$M9y[m.data$death==1&m.data$time>365.25*9]=0 40 
m.data$time9y=m.data$time 41 
m.data$time9y[m.data$time>365.25*9]=365.25*9 42 
###Cox early hazard phase (<9years) ### 43 
coxph(Surv(time9y, M9y==1)~RITA+strata(match.index), m.data) 44 
###Cox late hazard phase(≥9 years) ### 45 
coxph(Surv(time, death)~RITA+strata(match.index), m.data, subset=time≥365.25*9) 46 
 47 
  48 
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